Get the Stockscreener App
186.97
1.00%
-2.26
Beigene Ltd Adr stock is traded at $186.97, with a volume of 128.14K.
It is down -1.00% in the last 24 hours and down -14.44% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
See More
Previous Close:
$189.23
Open:
$186.92
24h Volume:
128.14K
Relative Volume:
0.42
Market Cap:
$19.72B
Revenue:
$3.10B
Net Income/Loss:
$-523.70M
P/E Ratio:
-11.20
EPS:
-16.6978
Net Cash Flow:
$-1.36B
1W Performance:
-8.63%
1M Performance:
-14.44%
6M Performance:
+8.38%
1Y Performance:
+0.25%
1-Day Range:
$184.49
$188.28
1-Week Range:
$184.49
$203.00
52-Week Range:
$126.97
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
Name
Beigene Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare BGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BGNE | 187.27 | 19.72B | 3.10B | -523.70M | -1.36B | -16.70 |
| VRTX | 467.37 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 760.78 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 230.58 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.54 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-20 | Downgrade | CLSA | Buy → Outperform |
| Mar-13-20 | Upgrade | Macquarie | Underperform → Neutral |
| Feb-18-20 | Resumed | Goldman | Buy |
| Jan-17-20 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-20 | Resumed | Morgan Stanley | Overweight |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-19-19 | Downgrade | UBS | Buy → Neutral |
| Nov-13-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-04-19 | Reiterated | Maxim Group | Buy |
| Jun-04-19 | Initiated | Bernstein | Outperform |
| May-10-19 | Upgrade | CLSA | Outperform → Buy |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Jan-04-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| May-17-18 | Reiterated | Maxim Group | Buy |
View All
Beigene Ltd Adr Stock (BGNE) Latest News
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene shares lift on raised price target to $260 from $254 - Investing.com
UBS Raises BeiGene (BGNE.US) TP to US$289.7 as 3Q Results Beat - AASTOCKS.com
BeiGene shares fall despite better-than-expected Q3 results - Investing.com
BeiGene shares fall despite better-than-expected Q3 results By Investing.com - Investing.com UK
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - GlobeNewswire Inc.
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com India
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
CMBI Eyes Opportunities in Innovative Medical Insurance, Prefers WuXi AppTec/ BeiGene/ INNOVENT BIO/ SKB BIO-B/ GIANT BIOGENE/ 3SBIO/ Mindray Bio-MedicalUS StocksGlobal News Content - AASTOCKS.com
Financial Fitness Check: Examining BeiGene Ltd ADR (BGNE)’s Key Ratios - The Dwinnex
The Potential Rise in the Price of BeiGene Ltd ADR (BGNE) following insiders activity - Knox Daily
Samsara Inc (IOT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Ginkgo Bioworks Holdings Inc (DNA) after recent insider movements - Knox Daily
Insider Sale Alert: PepsiCo Inc [PEP] – Is it Time to sell? - Knox Daily
VZIO (VIZIO Holding Corp) may reap gains as insiders became active recently - Knox Daily
Investing in Allegro Microsystems Inc. (ALGM) Is Getting More Attractive - Knox Daily
Investing in Alphatec Holdings Inc (ATEC): What You Must Know - Knox Daily
An Analysis of Mercury Systems Inc (MRCY)’s Potential Price Growth - Knox Daily
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
Royal Caribbean Group [RCL] Shares Rise 5.26 % on Wednesday - Knox Daily
Selling Buzz: UL Solutions Inc [ULS] 10% Owner ULSE Inc. sells 3,000,000 shares of the company - Knox Daily
Director Cui Xiangmin acquire 277,895 shares of Nuvation Bio Inc [NUVB] - Knox Daily
Taking a look at what insiders are doing to gauge the BeiGene Ltd ADR (BGNE)’s direction - Knox Daily
Stock Performance Spotlight: BeiGene Ltd ADR (BGNE) Ends the Day at 240.40, Up by 2.11 - The Dwinnex
Buying Buzz: Vuzix Corporation [VUZI] Director Harned Timothy Heydenreich purchases 20,000 shares of the company - Knox Daily
A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily
Director Stark Eugene S acquire 2,500 shares of Prospect Capital Corp [PSEC] - Knox Daily
It makes sense and dollars to buy BeiGene Ltd ADR (BGNE) stock - SETE News
Recent Insider Activity Could Benefit ACI Worldwide Inc (ACIW) - Knox Daily
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
A company insider recently sold 7,662 shares of S&P Global Inc [SPGI]. Should You Sale? - Knox Daily
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene's SVP sells shares worth nearly $285k By Investing.com - Investing.com UK
BeiGene executive sells over $1.1m in company shares By Investing.com - Investing.com South Africa
BeiGene executive sells over $1.1m in company shares - Investing.com India
BeiGene stock soars to 52-week high, touches $220 mark - Investing.com
A company insider recently sold 24 shares of Phreesia Inc [PHR]. Should You Sale? - Knox Daily
BeiGene adds new board member with financial expertise - Investing.com
BeiGene executive Wu Xiaobin sells over $1 million in company stock - Investing.com India
BeiGene (NASDAQ:BGNE) Now Covered by Analysts at JMP Securities - Defense World
JMP calls BeiGene a 'unique investment opportunity', sets $288 shares target By Investing.com - Investing.com
New additions to Roth MKM’s ADR portfolio for September - MSN
Opera Limited Sponsored ADR (OPRA) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Checking in on BeiGene Ltd ADR (BGNE) after recent insiders movement - Knox Daily
BeiGene stock touches 52-week high at $211.56 amid market fluctuations - Investing.com
Analyzing Jefferies Financial Group Inc (JEF) After Recent Trading Activity - Knox Daily
VICI Properties Inc [VICI] stock for 201,530 USD was bought by ABRAHAMSON JAMES R - Knox Daily
BeiGene executive sells $26,021 in company stock - Investing.com India
Beigene Ltd Adr Stock (BGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beigene Ltd Adr Stock (BGNE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| OYLER JOHN | Chief Executive Officer |
Oct 08 '24 |
Sale |
232.22 |
6,175 |
1,433,931 |
0 |
0.96%
6.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):